Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528112 · ClinicalTrials.gov registry record · Phase 3
Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,885
- Enrollment target
NCT00528112 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 2,885 participants.
The verdict
NCT00528112, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,885 participants
- Enrollment target
Study Summary
This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years
Interventions
- DRUG LCS12
- DRUG LCS16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,885 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528112
The ClinicalTrials.gov registry entry for NCT00528112 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,885 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LCS12 is the first listed.
NCT00528112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528112 about?
NCT00528112 is a clinical study titled "Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study". This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The stu...
What is the current status of trial NCT00528112?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,885 participants. The study started on 2007-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00528112?
The interventions under investigation include: LCS12 (DRUG), LCS16 (DRUG).
Who is sponsoring clinical trial NCT00528112?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.